# OssDsign > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ossdsign). ## Overview OssDsign is a Swedish medical technology company focused on products used in spine surgery and orthobiology. The group operates through OssDsign AB and its subsidiaries in the U.S., the U.K. and Scotland, with sales activities conducted through OssDsign USA Inc. ## Products & services • OssDsign Catalyst bone graft • Cranial PSI patient-specific implants • Orthobiology products for spinal fusion • Clinical evidence and surgeon support programs - **Spine orthobiology** (70%) — Bone graft and fusion products used in spinal procedures. - **Cranial implants** (20%) — Patient-specific cranial implant solutions for neurosurgical reconstruction. - **Clinical and commercial support** (10%) — Clinical evidence generation, education and market support around products. - OssDsign Catalyst bone graft - Cranial PSI patient-specific implants - Orthobiology products for spinal fusion - Clinical evidence and surgeon support programs ## Customers OssDsign sells primarily to hospitals, surgeons and healthcare systems that perform spine and cranial procedures. Its products are used in clinical settings where surgeons value evidence-backed implants and bone graft materials that support complex reconstructive and fusion cases. - **Hospitals and healthcare systems** (primary) — Buy products for surgical departments that treat spine and cranial reconstruction cases. - **Spine surgeons** (primary) — Use OssDsign Catalyst in fusion procedures where clinical evidence and handling matter. - **Neurosurgeons** (secondary) — Use Cranial PSI for patient-specific cranial reconstruction cases. - **Orthobiology distributors and channel partners** (secondary) — Support market access and product placement in selected geographies. - Hospitals and healthcare systems performing spine surgery - Neurosurgeons using patient-specific cranial implants - Orthopedic and spine surgeons seeking fusion solutions - Clinical teams that value published outcomes and evidence ## Geography OssDsign is headquartered in Uppsala, Sweden, but its commercial footprint is centered in the United States. The reports show U.S. net sales as the only disclosed geographic revenue market, and the company also maintains subsidiaries in England, Scotland and Maryland to support operations and sales. - **United States** (100%) — Only geographic revenue market disclosed in the report excerpt. - U.S. is the disclosed revenue market in the reports - Head office and parent company are based in Uppsala, Sweden - Sales activities are conducted through OssDsign USA Inc - Subsidiaries in England and Scotland support the group structure ## Strategy OssDsign’s strategy centers on building clinical evidence around OssDsign Catalyst and using that evidence to expand adoption with surgeons and hospitals. The company is also focused on scaling its U.S. commercial platform and broadening its product range to support long-term growth and eventual operating profitability. - **Clinical evidence generation** (short-term) — Published outcomes help differentiate the products in a crowded medtech market. - **U.S. commercial expansion** (medium-term) — The U.S. is the core revenue market and the main platform for scaling adoption. - **Product portfolio expansion** (medium-term) — A broader offering can increase procedure coverage and customer relevance. - Build clinical evidence to differentiate Catalyst - Expand U.S. sales and marketing coverage - Broaden product range in orthobiology - Use published outcomes to support surgeon adoption - Target long-term sales growth and cash generation ## Risks OssDsign faces typical medtech risks tied to regulation, product liability, intellectual property and clinical adoption. It also has financial exposure to foreign exchange, future financing needs and the concentration of sales in the U.S., which can amplify the impact of commercial or regulatory setbacks. - **Regulatory and licensing risk** [high] — Medical devices must meet government and industry requirements before sale and use. - **Product liability risk** [high] — Implantable products can create claims if outcomes or safety are challenged. - **Intellectual property risk** [medium] — The company depends on patents and know-how to protect its products. - **Foreign exchange risk** [medium] — Operations and sales span SEK, USD and other currencies. - **Future financing risk** [high] — Growth and product development can require external capital before cash generation. - Regulatory approvals and licenses are required for product commercialization - Product liability risk is inherent in implantable medical devices - Patent and IP protection are important to defend the product portfolio - Foreign exchange affects reported results and cost structure - Future financing needs may constrain growth execution ## Accounting OssDsign’s reporting is affected by capitalized development costs, intangible assets and impairment testing, all of which rely on management estimates. Revenue and gross margin can also move quarter to quarter because of product mix, customer mix, exchange rates and timing differences between production, inventory and end-customer sales. - **Capitalized development costs** — Reported operating expenses and intangible assets - **Impairment testing of intangibles** — Potential write-downs of goodwill or development assets - **Revenue timing and intra-group sales** — Quarterly comparability and revenue recognition timing - **Foreign exchange translation** — Reported revenue, gross margin and operating result - Capitalized product development affects reported operating expenses - Intangible asset impairment depends on future cash flow assumptions - Revenue timing can differ between parent and group sales - Quarterly gross margin is sensitive to product and customer mix - FX movements affect reported SEK revenue and costs --- *Last updated: 2026-08-11T04:04:55.158480+00:00*